The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study
- PMID: 30651999
- PMCID: PMC6328921
- DOI: 10.1002/ams2.382
The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study
Abstract
Aim: Continuous renal replacement therapy (CRRT) with a cytokine-adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface-treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons have been published to date. This study compared the efficacy, as measured by 28-day survival rates, of PMMA and AN69ST hemofilters in patients receiving CAH-CRRT.
Methods: This retrospective observational study reviewed the medical records of 142 patients who received CAH-CRRT between November 2013 and February 2015.
Results: The 28-day survival rates were higher in the AN69ST group than in the PMMA group for patients with or without sepsis (all patients, 79.4% versus 54.1%; patients with sepsis, 77.3% versus 50.0%; patients without sepsis, 83.3% versus 57.5%; P < 0.05). No significant differences were observed regarding 28-day survival rates of patients with or without sepsis (AN69ST, 77.3% versus 83.3%; P = 0.51; PMMA, 50.0% versus 57.5%; P = 0.61) using the same hemofilter.
Conclusion: The AN69ST hemofilter could be more effective than PMMA hemofilters for improving the survival outcomes of patients with or without sepsis.
Keywords: Acute kidney injury; renal replacement therapy; retrospective study; sepsis.
Figures



References
-
- Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit. Care Med. 2009; 37: 291–304. - PubMed
-
- Ronco C, Bellomo R, Homel P et al Effects of different doses in continuous veno‐venous hemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 2000; 9223: 26–30. - PubMed
-
- Cruz DN, Antonelli M, Fumagalli R et al Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445–52. - PubMed
LinkOut - more resources
Full Text Sources